Evidence map›Paper›PMID 41059258›Full record

ArticleTherapeutic advances in chronic disease2025

The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study.

Yao Dou, Jiawei Cui, Qi Gu, Xiwei Yuan, Mengmeng Hou, Wenjing Ni, Chen Dong, Chudi Chang, Jinhua Shao, Qiuling Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yao DouDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0000-0002-1757-3193
Jiawei CuiDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0000-0003-0310-7551
Qi GuDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Xiwei YuanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0000-0002-5257-8782
Mengmeng HouDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0000-0001-9961-8473
Wenjing NiDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Chen DongDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0000-0003-1183-5364
Chudi ChangDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China.ORCID https://orcid.org/0009-0008-4649-9050
Jinhua ShaoWuxi Hisky Medical Technologies Co., Ltd, Wuxi, China.
Qiuling WangWuxi Hisky Medical Technologies Co., Ltd, Wuxi, China.
Jie LiDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.ORCID https://orcid.org/0000-0003-0973-8645
Liang QiaoStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney at Westmead Hospital, 176 Hawkesbury Road, Westmead, NSW 2145, Australia.ORCID https://orcid.org/0000-0002-4723-8935
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei 050051, China.ORCID https://orcid.org/0000-0003-4192-099X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) has emerged as the most significant complication and leading cause of death among metabolic-associated fatty liver disease (MAFLD). Objectives: This study aims to investigate the CVD risk among MAFLD subgroups. Design: Data of participants from June 2017 to January 2023 in the Physical Examination Center of the Third Hospital of Hebei Medical University were collected. MAFLD were divided into four subgroups: metabolic healthy lean/normal weight MAFLD (MHL), metabolic healthy overweight/obese MAFLD (MHO), metabolic dysfunctional lean/normal weight MAFLD (MDL), and metabolic dysfunctional overweight/obese MAFLD (MDO). Methods: The risk assessment for atherosclerotic CVD was performed based on the flowchart for primary prevention risk assessment in Chinese adults. Results: The proportions of MHL, MHO, MDL, and MDO were 0.77% ( Conclusion: MAFLD is associated with a higher risk of CVD, especially in MDO. Classification of MAFLD based on body mass index and metabolic status helps in risk stratification, which will mitigate or prevent the development of CVD.

Indexed as

atherosclerotic cardiovascular diseaseslean/normal weightliver fibrosismetabolic-associated fatty liver diseasemetabolic dysfunction

Identifiers

PMID41059258
PMCPMC12497973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.